he replication of DNA. CIF (R7167) / CKI27 (R7304): CIF and CKI27 are targeted small-molecule agents developed by the company. The company has licensed them to Roche, and it is working on development overseas. GC33: GC33, a humanized antibody from Chugai research, targets glypican-3 proteins which are specifically expressed in liver cancer. The project involves joint research between Chugai and Tokyo University, as well as clinical proteomics work by PharmaLogicals Research, a joint venture in which it participates. The company is conducting Phase I overseas clinical trials. R1273: R1273 is a monoclonal antibody licensed from Roche. This is a class of targeted agents known as HER dimerization inhibitors, and is being developed for breast cancer. R7159 (GA101): R7159 is a humanized monoclonal antibody licensed from Roche. The company is conducting phase I domestic clinical trials for the intended indications of non-Hodgkin’s lymphoma. R1507: R1507 is a human anti-insulin like growth factor (IGF-1R) monoclonal antibody licensed from Roche. The company is conducting phase I domestic clinical trials. RENAL DISEASES FIELD Epogin: Erythropoietin is a hemopoietic factor produced mainly in the kidneys which speeds up erythrocyte production by acting on normoblastic progenitor cells found in bone marrow. The company has developed Epogin using gene recombinant technology. Epogin is a human erythropoietin formulation that uses epoetin beta as its main active ingredient. Erythropoietin is used for improving renal anemia primarily caused by the decline in erythropoietin production due to chronic renal failure. It also contributes to the improvement of a range of complications arising from anemia. R744 (overseas product name: Mircera): R744 is a new anemia treatment with a long serum half-life, enabling control of haemoglobin. R744 stimulates erythropoiesis by a different interaction with the erythropoietin receptor on progenitor cells in the bone marrow. Renagel: Renagel is used to treat hyperphosphatemia. Oxarol: Oxarol is an intravenous activated vitamin D3 derivative agent in Japan. It treats secondary hyperparathyroidism a result of prolonged dialysis by acting directly on the parathyroid gland to control PTH synthesis and secretion, and by acting to improve osteitis fibrosa and excess remodeling. BONE AND JOINT DISEASES FIELD In the field of bone and joint diseases, the company focuses on treatments for osteoporosis, osteoarthritis, and rheumatoid arthritis. Osteoporosis Evista: Evista, a new category of osteoporosis treatment called SERM, uses the estrogen-like effect for blocking the reduction of bone mass, while reducing the occurrence of gynecological adverse reactions that are associated with existing estrogen drugs. In Japan, Evista is jointly marketed by the company and Eli Lilly Japan. Alfarol: Alfarol, an activated vitamin D3 derivative, is a base drug for osteoporosis treatment. Alfarol inhibits the decline of bone mass by adjusting calcium and bone metabolism, and therefore prevents vertebrate fractures. ED-71: ED-71 is a vitamin D3 preparation. The company is developing it as a drug to replace Alfarol. It also prevents fractures. In May 2008, the company concluded a co-development and co-marketing agreement with Taisho Pharmaceutical Co., Ltd. R484 (overseas product name: Bonviva/Boniva): R484 is a bisphosphonate. It is available overseas in two dosage forms: a tablet that needs to be taken only once a month, and an injection that is given once every three months. The company has entered into a co-development and co-marketing agreement with Taisho Pharmaceutical Co., Ltd. for the development of R484. Rheumatoid Arthritis and Osteoarthritis Suvenyl: Suvenyl, a drug that improves joint function through injection into the joint cavity, is a high molecular weight hyaluronate sodium drug that alleviates knee joint pains caused by knee osteoarthritis and rheumatoid arthritis. Actemra: Actemra, an antibody drug, blocks the activity of interleukin-6 (IL- 6), a type of cytokine. In April 2008, the company obtained the domestic approval and launched for additional indi
chugai pharmaceutical co ltd
Nihonbashi Mitsui Tower
1-1 Nihonbashi-Muromachi 2-Chome
Phone: 81 3 3281 6611
Fax: 81 3 3281 6607www.chugai-pharm.co.jp
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for 4519.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact CHUGAI PHARMACEUTICAL CO LTD, please visit www.chugai-pharm.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.